Clinical trials: Ophthalmic Solutions
Chronic Ocular Pain
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and…
- Trial name
- NCT04630158
- Testing
- SAF312
- Where
- 28 sites in United States, Japan and 1 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Cataract
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
The purpose of this study is to demonstrate the non-inferiority of the study treatment (combined levofloxacin + dexamethasone eye drops) followed by dexamethasone eye drops alone vs.
- Trial name
- LEADER7 (NCT03739528)
- Testing
- Levofloxacin + dexamethasone followed by dexamethasone, Tobramycin + Dexamethasone
- Where
- 57 sites in Italy
- Volunteers
- 808 people
- Sponsor
- NTC srl
Uveitis, Iritis
Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications
Retinal optical coherence tomography (OCT) is an established technology which enables a detailed cross-sectional visualization of the retinal micro-anatomy, and an objective measurement of its thickness in-vivo.
- Conditions
- Uveitis, Iritis, Iridocyclitis, Anterior Uveitis
- Trial name
- NCT00476593
- Testing
- Diclofenac, Dexamethasone
- Where
- 2 sites in Norway
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Refractive Error
Clear Care® Plus vs. PeroxiClear™
The purpose of this study is to evaluate Clear Care® Plus compared to PeroxiClear™ for mean residual peroxide in used lens cases collected at Day 30 after neutralization at recommended storage time.
- Trial name
- NCT02413333
- Testing
- Clear Care Plus contact lens solution, PeroxiClear contact lens solution, Silicone hydrogel contact lenses
- Volunteers
- 133 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease
This study will investigate the safety, efficacy and acceptability of two new eye drop formulations compared with Refresh Tears® in patients with dry eye disease.
- Trial name
- NCT01294384
- Testing
- carboxymethylcellulose sodium based New Eye Drop Formulation 1, carboxymethylcellulose sodium based New Eye Drop Formulation 2, carboxymethylcellulose sodium based Eye Drops
- Where
- 2 sites in Australia, Canada
- Volunteers
- 305 people
- Sponsor
- Allergan
Bacterial Conjunctivitis
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
The objective of this study is to evaluate the safety and efficacy of Besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (TID) for seven days…
- Trial name
- NCT01330355
- Testing
- Besivance, Gatifloxacin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Efficacy and Safety Study of FID 119515A
The purpose of this study was to compare the effect of FID 119515A to Blink® Tears on the integrity of tear film in adults with a history of dry eye in both eyes.
- Trial name
- NCT01833117
- Testing
- FID 119515A, Blink® Tears
- Volunteers
- 75 people
- Sponsor
- Alcon Research
Dry Eye
Tobramycin Tear Concentrations
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
- Trial name
- NCT00695435
- Testing
- TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, TOBREX Ophthalmic Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Cataract
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
The purpose of this study is to evaluate the penetration of levofloxacin and dexamethasone 21-phosphate into the aqueous humour after ocular administration in combination or as single active ingredients.
- Trial name
- iPERME (NCT03740659)
- Testing
- Levofloxacin + Dexamethasone, Levofloxacin, Dexamethasone
- Where
- 2 sites in Italy
- Volunteers
- 125 people
- Sponsor
- NTC srl
Glaucoma, Ocular Hypertension
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with carteolol long-acting ophthalmic solution in subjects who are insufficiently responsive to carteolol…
- Trial name
- NCT02105285
- Testing
- OPC-1085EL ophthalmic solution, Carteolol long-acting ophthalmic solution
- Where
- Japan
- Volunteers
- 193 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye, Dry Eye Syndromes
Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time.
- Trial name
- NCT03417505
- Testing
- Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tangible Science
Sjogren's Syndrome, Dry Eye
Nasal Spray Study in Sjogren's Dry Eye Disease
This study will investigate how well OC-01 (varenicline) nasal spray can treat the signs and symptoms of dry eye disease in those Sjogren's Syndrome.
- Trial name
- NCT05700422
- Testing
- Varenicline Nasal Spray
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Dry Eye Disease
Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease
This is a phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the safety and tolerability and ocular efficacy of SY-201 Ophthalmic Solution versus vehicle…
- Trial name
- NCT05370495
- Testing
- SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Seinda Pharmaceutical Guangzhou Corporation
Geographic Atrophy, Age-Related Macular Degeneration
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
Othera Pharmaceuticals' Othera (OT)-551 antioxidant eye drop has the potential for chronic treatment of the dry form of age-related macular degeneration.
- Conditions
- Geographic Atrophy, Age-Related Macular Degeneration, AMD
- Trial name
- NCT00306488
- Testing
- OT-551 antioxidant eye drop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Conjunctivitis, Bacterial
Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis.
- Trial name
- PRO-157 (NCT03696342)
- Testing
- Pazufloxacin, Zymar
- Where
- 6 sites in Mexico
- Volunteers
- 46 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- AC-170 (NCT01332188)
- Testing
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Ocular Discomfort
A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution
The objective of this study is to evaluate the clinical performance of Bausch \& Lomb investigational Multi-Purpose Solution compared to Ciba Vision Multi-Purpose Solution when used by wearers of silicone hydrogel or Group IV…
- Trial name
- NCT01024751
- Testing
- Bausch & Lomb Multi-Purpose Solution, Ciba's Multi-Purpose Solution
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Conjunctivitis, Allergic
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
- Trial name
- NCT00424398
- Testing
- Bepreve, Bepotastine Besilate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease
A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT05424549
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- Aldeyra Therapeutics, Inc.